SCHEMBL24779751

SCHEMBL24779751

CC(C)(C)OC(=O)N1CCN(n2cc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.47
▸ FFAR1 O14842 1/20 0.44
▸ HTT P42858 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ F13A1 P00488 2/20 0.37
▸ TGM2 P21980 2/20 0.37
▸ TGM1 P22735 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ BACE1 P56817 1/20 0.36
▸ BACE2 Q9Y5Z0 1/20 0.36
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ RET P07949 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31168267 0.83 FFAR1 (0.51) USP30FFAR1HTTATMUSP2
SCHEMBL31168266 0.83 FFAR1 (0.51) USP30FFAR1HTTATMUSP2
SCHEMBL31168261 0.83 FFAR1 (0.51) USP30FFAR1HTTATMUSP2
SCHEMBL12439731 0.82 FFAR1 (0.50) USP30FFAR1HTTATMUSP2
SCHEMBL320828 0.81 USP30 (0.52) USP30FFAR1BACE1DDB1CRBN
SCHEMBL15726271 0.80 FFAR1 (0.48) USP30FFAR1LMNA
SCHEMBL15377252 0.80 FFAR1 (0.50) USP30FFAR1USP2SMN1; SMN2GPR119
SCHEMBL17122082 0.79 USP30 (0.51) USP30FFAR1MAPTDDB1CRBN
SCHEMBL2799598 0.79 USP30 (0.51) USP30FFAR1BACE1GPR119
SCHEMBL17122079 0.79 USP30 (0.47) USP30FFAR1USP2SMN1; SMN2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 — — US disclosed
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 — — US disclosed
US-20220402921-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2022-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, DYRK3 USP30 4750/4885FFAR1 4299/4885HTT 682/4885
US-20220402921-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, DYRK3 USP30 4750/4885FFAR1 4299/4885HTT 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback